Endothelin and vascular function in liver disease

K Moore, K Moore

Abstract

The endothelins are a group of three related peptides with two receptor subtypes, ET(A) and ET(B). Following the discovery of endothelin 1 as a potent vasoconstrictor, there has been intense interest in the role of endothelin on vascular function in liver disease. Speculation on the role of endothelin in the pathogenesis of acute renal failure, including hepatorenal syndrome, has also been speculated.

References

    1. Yanigasawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by. Nature 1988;332:411–15.
    1. La M, Reid JJ. Endothelin-1 and the regulation of vascular tone. Clin Exp Pharmacol Physiol 1995;22:315–23.
    1. Firth JD, Ratcliffe PJ, Raine AE, et al. Endothelin: an important factor in acute renal failure? Lancet 1988;2:1179–82.
    1. Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 1977;37:635–42.
    1. Simonson MS, Dunn MJ. Endothelin-1 stimulates contraction of rat glomerular mesangial cells and potentiates beta-adrenergic-mediated cyclic adenosine monophosphate accumulation. J Clin Invest 1990;85:790–7.
    1. Gulberg V, Gerbes AL, Vollmar AM, et al. Endothelin-3 like immunoreactivity in plasma of patients with cirrhosis of the liver. Life Sci 1992;51:1165–9.
    1. Uemasu J, Matsumoto H, Kawasaki H. Increased plasma endothelin levels in patients with liver cirrhosis. Nephron 1992;60:380.
    1. Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992;327:1774–8.
    1. Bachmann-Brandt S, Bittner I, Neuhaus P, et al. Plasma levels of endothelin-1 in patients with the hepatorenal syndrome after successful liver transplantation. Transpl Int 2000;13:357–62.
    1. Kapoor D, Redhead DN, Hayes PC, et al. Systemic and regional changes in plasma endothelin following transient increase in portal pressure. Liver Transplant 2003;9:32–9.
    1. Anand R, Harry D, Holt S, et al. Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure. Gut 2002;50:111–17.
    1. Ghandhi CR, Stephenson K, Olson MS. Endothelin, a potent peptide agonist in the liver. J Biol Chem 1990;265:17432–5.
    1. Serradeil-Le Gal C, Jouneaux C, Sanchez-Bueno A, et al. Endothelin action in rat liver. Receptors, free Ca2+ oscillations, and activation of glycogenolysis. J Clin Invest 1991;87:133–8.
    1. Pinzani M, Gentilini P. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 1999;19:397–410.
    1. Pinzani M, Marra F, Carloni V. Signal transduction in hepatic stellate cells. Liver 1998;18:2–13.
    1. Rockey DC. Characterization of endothelin receptors mediating rat hepatic stellate cell contraction. Biochem Biophys Res Commun 1995;207:725–31.
    1. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology 1996;24:233–40.
    1. Kawada N, Kuroki T, Kobayashi K, et al. Action of endothelins on hepatic stellate cells. J Gastroenterol 1995;30:731–8.
    1. Kawada N, Tran-Thi TA, Klein H, et al. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 1993;213:815–23.
    1. Pinzani M, Milani S, De Franco R, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996;110:534–48.
    1. Yokomori H, Oda M, Yasogawa Y, et al. Enhanced expression of endothelin B receptor at protein and gene levels in human cirrhotic liver. Am J Pathol 2001;159:1353–62.
    1. Alam I, Bass NM, Bacchetti P, et al. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol 2000;95:199–203.
    1. Leivas A, Jimenez W, Bruix J, et al. Gene expression of endothelin-1 and ET(A) and ET(B) receptors in human cirrhosis: relationship with hepatic hemodynamics. J Vasc Res 1998;35:186–93.
    1. Gerbes AL, Moller S, Gulberg V, et al. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 1995;21:735–9.
    1. Moller S, Gulberg V, Henriksen JH, et al. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 1995;23:135–44.
    1. Nagasue N, Dhar DK, Yamanoi A, et al. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology 2000;31:1107–14.
    1. Pannen BH, Bauer M, Zhang JX, et al. Endotoxin pretreatment enhances portal venous contractile response to endothelin-1. Am J Physiol 1996;270 (1 pt 2) :H7–15.
    1. Yokoyama Y, Baveja R, Kresge N, et al. Endothelin receptor remodeling induces the portal venous hyper-response to endothelin-1 following endotoxin pretreatment. Shock 2002;17:36–40.
    1. Reichen J, Gerbes AL, Steiner MJ, et al. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol 1998;28:1020–30.
    1. Kojima H, Yamao J, Tsujimoto T, et al. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J Hepatol 2000;32:43–50.
    1. Helmy A, Jalan R, Newby DE, et al. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology 2001;33:826–31.
    1. Helmy A, Newby DE, Jalan R, et al. Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut 2003;52:410–15.
    1. Vaughan RB, Angus PW, Chin-Dusting JP. Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation. Gut 2003;52:1505–10.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren